本文選題：腦膜炎球菌多糖疫苗 + 成本效益分析　； 參考：《中國疫苗和免疫》2017年04期

【摘要】：目的探討貴州省腦膜炎球菌多糖疫苗(Meningococcal polysaccharide vaccine,MPV)推廣使用和納入免疫規(guī)劃后的成本效益。方法抽樣調(diào)查流行性腦脊髓膜炎(流腦)病例住院、非住院治療費用、陪護費用以及MPV接種投入經(jīng)費,計算流腦患病的直接和間接費用、流腦患病造成死亡和傷殘的經(jīng)濟損失,以及接種MPV的成本效益比值和產(chǎn)生的凈效益。結(jié)果貴州省MPV推廣使用和納入免疫規(guī)劃后,1990-2015年全省預(yù)計減少流腦發(fā)病94 069例,減少致殘13 170例,減少死亡10 710例。每例流腦病例患病后減少社會產(chǎn)值88.65萬元。適齡兒童因接種MPV而產(chǎn)生的凈效益為102.86億元,成本效益比值為1∶13.54。結(jié)論接種MPV對降低貴州省流腦發(fā)病水平效果顯著,可產(chǎn)生較好的經(jīng)濟效益。
[Abstract]:Objective to investigate the cost-effectiveness of meningococcal polysaccharide vaccine (MPV) in Guizhou province. Methods A sample of patients with epidemic cerebrospinal meningitis (meningitis) was investigated. The cost of hospitalization, non-hospital treatment, accompanying care and MPV inoculation investment were investigated. The direct and indirect costs of meningitis were calculated, and the economic losses of death and disability caused by meningitis were calculated. And the cost-benefit ratio and net benefit of inoculation with MPV. Results after MPV was popularized and included in immunization program in Guizhou province, 94,069 cases of meningitis, 13,170 cases of disability and 10,710 cases of death were expected to be reduced from 1990 to 2015. The social output value was reduced by 886500 yuan after each case of meningitis became ill. The net benefit of inoculation with MPV was 10.286 billion yuan and the cost benefit ratio was 1: 13.54. Conclusion inoculation of MPV has a significant effect on reducing the level of cerebrospinal meningitis in Guizhou province, and can produce better economic benefits.
【作者單位】： 貴州省疾病預(yù)防控制中心;
【分類號】：R186;R515.2

【相似文獻】

相關(guān)期刊論文 前4條

1 傅繼華,阮玉華,康殿民,張遵寶,張興錄,王克安;山東省腎綜合征出血熱滅活疫苗接種的成本效益分析[J];中華預(yù)防醫(yī)學(xué)雜志;2001年01期

2 邱玉中;以成本效益分析評價補充維生素A的策略目標(biāo)[J];國外醫(yī)學(xué)(醫(yī)院管理分冊);1998年03期

3 林瑞珍,尉成芳;應(yīng)用一次性免疫注射針的成本效益分析[J];江蘇預(yù)防醫(yī)學(xué);1998年03期

4 林楊;消滅疾病的成本效益[J];中國計劃免疫;1996年06期

，

本文編號：1922561